Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Denosumab biosimilar - Biocon Biologics

Next Previous
Drug Profile

Denosumab biosimilar - Biocon Biologics

Alternative Names: Aukelso; Bmab-1000; BOSAYA; Bosaya; denosumab-kyqq; Evfraxy; VEVZUO; Vevzuo

Latest Information Update: 30 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocon Biologic
  • Developer Biocon; Biocon Biologics
  • Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bone disorders; Corticosteroid-induced osteoporosis; Giant cell tumour of bone; Osteoporosis; Postmenopausal osteoporosis
  • Registered Giant cell tumours; Male osteoporosis; Malignant hypercalcaemia

Most Recent Events

  • 02 Jun 2026 Pharmacokinetics and adverse events data from a phase I PK trial presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO 2026)
  • 02 Jun 2026 Biocon Biologics completes a phase I pharmacokinetics trial for Healthy volunteers (SC) prior to June 2026 (CTRI/2024/02/063265) (700395490)
  • 28 Apr 2026 No recent reports of development identified for phase-I development in Osteoporosis(In volunteers) in USA (SC, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top